JP6040943B2 - 新規抗ヒトｃｔｇｆ抗体 - Google Patents

新規抗ヒトｃｔｇｆ抗体 Download PDF

Info

Publication number
JP6040943B2
JP6040943B2 JP2013550349A JP2013550349A JP6040943B2 JP 6040943 B2 JP6040943 B2 JP 6040943B2 JP 2013550349 A JP2013550349 A JP 2013550349A JP 2013550349 A JP2013550349 A JP 2013550349A JP 6040943 B2 JP6040943 B2 JP 6040943B2
Authority
JP
Japan
Prior art keywords
antibody
human
variable region
chain variable
human ctgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013550349A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013094723A1 (ja
Inventor
正司 岩崎
正司 岩崎
隆一 守屋
隆一 守屋
正康 吉野
正康 吉野
浩二 ▲高▼倉
浩二 ▲高▼倉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JPWO2013094723A1 publication Critical patent/JPWO2013094723A1/ja
Application granted granted Critical
Publication of JP6040943B2 publication Critical patent/JP6040943B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013550349A 2011-12-22 2012-12-21 新規抗ヒトｃｔｇｆ抗体 Expired - Fee Related JP6040943B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011281811 2011-12-22
JP2011281811 2011-12-22
PCT/JP2012/083206 WO2013094723A1 (ja) 2011-12-22 2012-12-21 新規抗ヒトｃｔｇｆ抗体

Publications (2)

Publication Number Publication Date
JPWO2013094723A1 JPWO2013094723A1 (ja) 2015-04-27
JP6040943B2 true JP6040943B2 (ja) 2016-12-07

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013550349A Expired - Fee Related JP6040943B2 (ja) 2011-12-22 2012-12-21 新規抗ヒトｃｔｇｆ抗体

Country Status (16)

Country Link
US (1) US9587015B2 (enExample)
EP (1) EP2796550B1 (enExample)
JP (1) JP6040943B2 (enExample)
KR (1) KR20140107507A (enExample)
CN (1) CN104011206B (enExample)
AR (1) AR089425A1 (enExample)
BR (1) BR112014015405A2 (enExample)
CA (1) CA2859627A1 (enExample)
EA (1) EA029290B1 (enExample)
ES (1) ES2665851T3 (enExample)
IN (1) IN2014CN04615A (enExample)
MX (1) MX345019B (enExample)
PL (1) PL2796550T3 (enExample)
PT (1) PT2796550T (enExample)
TW (1) TW201333034A (enExample)
WO (1) WO2013094723A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
MY208454A (en) * 2019-06-04 2025-05-09 Shanghai hengrui pharmaceutical co ltd Anti-connective tissue growth factor antibody and application thereof
AU2021390125A1 (en) * 2020-12-03 2023-06-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
US20250163158A1 (en) 2022-06-07 2025-05-22 Astellas Pharma Inc. Pharmaceutical composition containing anti-integrin alpha11 antibody for treatment or prevention of aging-related diseases
WO2024095964A1 (ja) 2022-10-31 2024-05-10 アステラス製薬株式会社 Ｔｏｌｌ様受容体７／８デュアルアゴニスト化合物を含む抗体薬物複合体
TW202502816A (zh) * 2023-03-10 2025-01-16 大陸商上海濟煜醫藥科技有限公司 一種靶向ｃｔｇｆ的抗體或其抗原結合片段及其應用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
KR100337069B1 (ko) 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
WO1999033878A1 (en) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
JP4537507B2 (ja) 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US6492129B1 (en) * 1998-12-14 2002-12-10 University Of Miami Fragments of connective tissue growth factor that induce extracellular matrix synthesis, collagen synthesis and/or myofibroblast differentiation
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
ES2665851T3 (es) 2018-04-27
MX345019B (es) 2017-01-11
EP2796550A4 (en) 2015-08-19
EA201491240A1 (ru) 2014-11-28
EP2796550B1 (en) 2018-02-28
PT2796550T (pt) 2018-04-18
US20140343258A1 (en) 2014-11-20
CN104011206A (zh) 2014-08-27
CA2859627A1 (en) 2013-06-27
WO2013094723A1 (ja) 2013-06-27
EP2796550A1 (en) 2014-10-29
US9587015B2 (en) 2017-03-07
CN104011206B (zh) 2017-03-08
TW201333034A (zh) 2013-08-16
KR20140107507A (ko) 2014-09-04
EA029290B1 (ru) 2018-03-30
IN2014CN04615A (enExample) 2015-09-18
AR089425A1 (es) 2014-08-20
JPWO2013094723A1 (ja) 2015-04-27
PL2796550T3 (pl) 2018-08-31
BR112014015405A2 (pt) 2017-06-13
MX2014007681A (es) 2014-11-25

Similar Documents

Publication Publication Date Title
JP6040943B2 (ja) 新規抗ヒトｃｔｇｆ抗体
JP5941049B2 (ja) ヒトｔｗｅａｋに対する抗体およびその使用
KR20030014272A (ko) 인간 ｍｃｐ-1에 대한 항체
KR101589135B1 (ko) 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
JP2012528117A (ja) 幹細胞の標的化
JP7415939B2 (ja) 抗ヒトＦｎ１４抗体
US10670604B2 (en) PCSK9 antibody, and pharmaceutical composition and use thereof
KR20140047116A (ko) 신규 항 인간 ngf 항체
JP5971238B2 (ja) 新規抗ヒトｉｌ−２３受容体抗体
CN110818793A (zh) 抗IL-1β的抗体、其药物组合物及其用途
KR20170052655A (ko) 혈관내피 리파제의 효소 활성을 저해하는 인간화 모노클로널 항체
JP6137169B2 (ja) 新規抗ヒトｉｌ−２３受容体抗体
US20220325000A1 (en) Monoclonal antibody which targets tfpi
TW202325739A (zh) 新穎Nav1.7單株抗體
JP2021526833A (ja) Ａｐｊ抗体及びｅｌａｂｅｌａとのその融合タンパク質並びにその医薬組成物及び用途
RU2787044C2 (ru) АНТИТЕЛО ПРОТИВ Fn14 ЧЕЛОВЕКА
WO2025256571A1 (zh) 靶向b7h7和cd3的双特异性抗体及其应用
WO2024002145A1 (zh) 结合il-17a和il-17f的抗体分子及其应用
JP2025535498A (ja) Ｃｄ２４に対する抗体およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151211

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160923

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161024

R150 Certificate of patent or registration of utility model

Ref document number: 6040943

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees